NG-350A
Mismatch Repair-Proficient (pMMR) Locally Advanced Rectal Cancer (LARC)
Phase 1bActive
Key Facts
Indication
Mismatch Repair-Proficient (pMMR) Locally Advanced Rectal Cancer (LARC)
Phase
Phase 1b
Status
Active
Company
About Akamis Bio
Akamis Bio is a private, clinical-stage biotech targeting the significant unmet need in colorectal cancer with its proprietary T-SIGn® oncolytic immunotherapy platform. The company's lead program, NG-350A, is in a Phase 1b trial (FORTRESS) for mismatch repair-proficient locally advanced rectal cancer, with initial data expected at AACR 2026. With a focused pipeline, experienced leadership, and a capital-efficient, entrepreneurial ethos, Akamis aims to transform treatment paradigms by potentially reducing the need for invasive surgeries and improving patient quality of life.
View full company profile